| __timestamp | Amphastar Pharmaceuticals, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 17763000 |
| Thursday, January 1, 2015 | 46974000 | 22180000 |
| Friday, January 1, 2016 | 47298000 | 37257000 |
| Sunday, January 1, 2017 | 50918000 | 27367000 |
| Monday, January 1, 2018 | 58044000 | 64770000 |
| Tuesday, January 1, 2019 | 63109000 | 74986000 |
| Wednesday, January 1, 2020 | 65157000 | 79256000 |
| Friday, January 1, 2021 | 68920000 | 100156000 |
| Saturday, January 1, 2022 | 66592000 | 131408000 |
| Sunday, January 1, 2023 | 80393000 | 152946000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding the financial dynamics of companies is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Dynavax Technologies Corporation have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, starting at $40 million and reaching $80 million. In contrast, Dynavax experienced a staggering 760% increase, from $18 million to $153 million.
This divergence highlights Dynavax's aggressive expansion and investment in administrative capabilities, especially post-2018, where their expenses surged by over 100% in just five years. Meanwhile, Amphastar maintained a steady growth trajectory, reflecting a more conservative financial strategy. These insights provide a window into each company's operational priorities and market strategies, offering valuable lessons for investors and industry analysts alike.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
TG Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.